Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-08-11

Clinical Trial Update: Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lapatinib with or without trastuzumab added to standard neoadjuvant therapy for breast cancer; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • HERCEPTIN (trastuzumab)
  • Tykerb (lapatinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Breast | Phase 2 | Status: COMPLETED | Results posted: 2011-08-11